<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39457672</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Peptide-Based Inhibitors of Protein-Protein Interactions (PPIs): A Case Study on the Interaction Between SARS-CoV-2 Spike Protein and Human Angiotensin-Converting Enzyme 2 (hACE2).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2361</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines12102361</ELocationID><Abstract><AbstractText>Protein-protein interactions (PPIs) are fundamental to many critical biological processes and are crucial in mediating essential cellular functions across diverse organisms, including bacteria, parasites, and viruses. A notable example is the interaction between the SARS-CoV-2 spike (S) protein and the human angiotensin-converting enzyme 2 (hACE2), which initiates a series of events leading to viral replication. Interrupting this interaction offers a promising strategy for blocking or significantly reducing infection, highlighting its potential as a target for anti-SARS-CoV-2 therapies. This review focuses on the hACE2 and SARS-CoV-2 spike protein interaction, exemplifying the latest advancements in peptide-based strategies for developing PPI inhibitors. We discuss various approaches for creating peptide-based inhibitors that target this critical interaction, aiming to provide potential treatments for COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rakhmetullina</LastName><ForeName>Aizhan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0117-7110</Identifier><AffiliationInfo><Affiliation>Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zielenkiewicz</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8151-6874</Identifier><AffiliationInfo><Affiliation>Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Biology, Institute of Experimental Plant Biology and Biotechnology, University of Warsaw, Miecznikowa 1, 02-096 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odolczyk</LastName><ForeName>Norbert</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Systems Biology, Institute of Experimental Plant Biology and Biotechnology, University of Warsaw, Miecznikowa 1, 02-096 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>79/E35/SPUB/SP/2019; DIR/Wk/2018/06</GrantID><Agency>This research was partially funded by the Polish Ministry of Science and Higher Education, under the projects and POL-OPENSCREEN</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE2</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">angiotensin-converting enzyme 2</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">drug design</Keyword><Keyword MajorTopicYN="N">inhibitors of protein–protein interactions</Keyword><Keyword MajorTopicYN="N">peptides</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39457672</ArticleId><ArticleId IdType="pmc">PMC11504900</ArticleId><ArticleId IdType="doi">10.3390/biomedicines12102361</ArticleId><ArticleId IdType="pii">biomedicines12102361</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Henninot A., Collins J.C., Nuss J.M. The Current State of Peptide Drug Discovery: Back to the Future? J. Med. Chem. 2018;61:1382–1414. doi: 10.1021/acs.jmedchem.7b00318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.7b00318</ArticleId><ArticleId IdType="pubmed">28737935</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Wang N., Zhang W., Cheng X., Yan Z., Shao G., Wang X., Wang R., Fu C. Therapeutic Peptides: Current Applications and Future Directions. Signal Transduct. Target. Ther. 2022;7:48. doi: 10.1038/s41392-022-00904-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00904-4</ArticleId><ArticleId IdType="pmc">PMC8844085</ArticleId><ArticleId IdType="pubmed">35165272</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A.C.-L., Harris J.L., Khanna K.K., Hong J.-H. A Comprehensive Review on Current Advances in Peptide Drug Development and Design. Int. J. Mol. Sci. 2019;20:2383. doi: 10.3390/ijms20102383.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20102383</ArticleId><ArticleId IdType="pmc">PMC6566176</ArticleId><ArticleId IdType="pubmed">31091705</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau J.L., Dunn M.K. Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions. Bioorganic Med. Chem. 2018;26:2700–2707. doi: 10.1016/j.bmc.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2017.06.052</ArticleId><ArticleId IdType="pubmed">28720325</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabri W., Cantelmi P., Corbisiero D., Fantoni T., Ferrazzano L., Martelli G., Mattellone A., Tolomelli A. Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives. Front. Mol. Biosci. 2021;8:697586. doi: 10.3389/fmolb.2021.697586.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.697586</ArticleId><ArticleId IdType="pmc">PMC8236712</ArticleId><ArticleId IdType="pubmed">34195230</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolopoulos V., Bojarska J., Chai T.-T., Elnagdy S., Kaczmarek K., Matsoukas J., New R., Parang K., Lopez O.P., Parhiz H., et al. A Global Review on Short Peptides: Frontiers and Perspectives. Molecules. 2021;26:430. doi: 10.3390/molecules26020430.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26020430</ArticleId><ArticleId IdType="pmc">PMC7830668</ArticleId><ArticleId IdType="pubmed">33467522</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarracino D.A., Iannaccone J., Cabrera A., Kancharla S. Harnessing the Therapeutic Potential and Biological Activity of Antiviral Peptides. ChemBioChem. 2022;23:e202200415. doi: 10.1002/cbic.202200415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.202200415</ArticleId><ArticleId IdType="pubmed">36075015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahan R., Worm D.J., de Castro G.V., Ng S., Barnard A. Modulators of Protein–Protein Interactions as Antimicrobial Agents. RSC Chem. Biol. 2021;2:387–409. doi: 10.1039/D0CB00205D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0CB00205D</ArticleId><ArticleId IdType="pmc">PMC8341153</ArticleId><ArticleId IdType="pubmed">34458791</ArticleId></ArticleIdList></Reference><Reference><Citation>Poluri K.M., Gulati K., Tripathi D.K., Nagar N. Protein-Protein Interactions in Host–Pathogen Interactions. In: Poluri K.M., Gulati K., Tripathi D.K., Nagar N., editors. Protein-Protein Interactions: Pathophysiological and Therapeutic Aspects: Volume II. Springer Nature; Singapore: 2023. pp. 207–264.</Citation></Reference><Reference><Citation>de Groot N.S., Burgas M.T. Bacteria Use Structural Imperfect Mimicry to Hijack the Host Interactome. PLoS Comput. Biol. 2020;16:e1008395. doi: 10.1371/journal.pcbi.1008395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1008395</ArticleId><ArticleId IdType="pmc">PMC7744059</ArticleId><ArticleId IdType="pubmed">33275611</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q., Zhang L., et al. Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor. Nature. 2020;581:215–220. doi: 10.1038/s41586-020-2180-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 Entry into Cells. Nat. Rev. Mol. Cell Biol. 2022;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Wu Y., Yao S., Ge H., Zhu Y., Chen K., Chen W., Zhang Y., Zhu W., Wang H., et al. Discovery of Potential Small Molecular SARS-CoV-2 Entry Blockers Targeting the Spike Protein. Acta Pharmacol. Sin. 2022;43:788–796. doi: 10.1038/s41401-021-00735-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-021-00735-z</ArticleId><ArticleId IdType="pmc">PMC8334341</ArticleId><ArticleId IdType="pubmed">34349236</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodríguez Y., Cardoze S.M., Obineche O.W., Melo C., Persaud A., Fernández Romero J.A. Small Molecules Targeting SARS-CoV-2 Spike Glycoprotein Receptor-Binding Domain. ACS Omega. 2022;7:28779–28789. doi: 10.1021/acsomega.2c00844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.2c00844</ArticleId><ArticleId IdType="pmc">PMC9380817</ArticleId><ArticleId IdType="pubmed">35991504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau E.Y., Negrete O.A., Bennett W.F.D., Bennion B.J., Borucki M., Bourguet F., Epstein A., Franco M., Harmon B., He S., et al. Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline. Front. Mol. Biosci. 2021;8:678701. doi: 10.3389/fmolb.2021.678701.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.678701</ArticleId><ArticleId IdType="pmc">PMC8315004</ArticleId><ArticleId IdType="pubmed">34327214</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr A.R., Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. In: Maier H.J., Bickerton E., Britton P., editors. Coronaviruses: Methods and Protocols. Springer; New York, NY, USA: 2015. pp. 1–23. Methods in Molecular Biology.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369385</ArticleId><ArticleId IdType="pubmed">25720466</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Fan Y., Lai Y., Han T., Li Z., Zhou P., Pan P., Wang W., Hu D., Liu X., et al. Coronavirus Infections and Immune Responses. J. Med. Virol. 2020;92:424–432. doi: 10.1002/jmv.25685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25685</ArticleId><ArticleId IdType="pmc">PMC7166547</ArticleId><ArticleId IdType="pubmed">31981224</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Yang C., Xu X., Xu W., Liu S. Structural and Functional Properties of SARS-CoV-2 Spike Protein: Potential Antivirus Drug Development for COVID-19. Acta Pharmacol. Sin. 2020;41:1141–1149. doi: 10.1038/s41401-020-0485-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-020-0485-4</ArticleId><ArticleId IdType="pmc">PMC7396720</ArticleId><ArticleId IdType="pubmed">32747721</ArticleId></ArticleIdList></Reference><Reference><Citation>Satarker S., Nampoothiri M. Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2. Arch. Med. Res. 2020;51:482–491. doi: 10.1016/j.arcmed.2020.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2020.05.012</ArticleId><ArticleId IdType="pmc">PMC7247499</ArticleId><ArticleId IdType="pubmed">32493627</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F., Li W., Farzan M., Harrison S.C. Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor. Science. 2005;309:1864–1868. doi: 10.1126/science.1116480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1116480</ArticleId><ArticleId IdType="pubmed">16166518</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Petitjean S.J.L., Koehler M., Zhang Q., Dumitru A.C., Chen W., Derclaye S., Vincent S.P., Soumillion P., Alsteens D. Molecular Interaction and Inhibition of SARS-CoV-2 Binding to the ACE2 Receptor. Nat. Commun. 2020;11:4541. doi: 10.1038/s41467-020-18319-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18319-6</ArticleId><ArticleId IdType="pmc">PMC7486399</ArticleId><ArticleId IdType="pubmed">32917884</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., Chen P., Wang J., Feng J., Zhou H., Li X., Zhong W., Hao P. Evolution of the Novel Coronavirus from the Ongoing Wuhan Outbreak and Modeling of Its Spike Protein for Risk of Human Transmission. Sci. China Life Sci. 2020;63:457–460. doi: 10.1007/s11427-020-1637-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-020-1637-5</ArticleId><ArticleId IdType="pmc">PMC7089049</ArticleId><ArticleId IdType="pubmed">32009228</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q. Structural Basis for the Recognition of SARS-CoV-2 by Full-Length Human ACE2. Science. 2020;367:1444–1448. doi: 10.1126/science.abb2762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2762</ArticleId><ArticleId IdType="pmc">PMC7164635</ArticleId><ArticleId IdType="pubmed">32132184</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A., Li F. Structural Basis of Receptor Recognition by SARS-CoV-2. Nature. 2020;581:221–224. doi: 10.1038/s41586-020-2179-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2179-y</ArticleId><ArticleId IdType="pmc">PMC7328981</ArticleId><ArticleId IdType="pubmed">32225175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.-L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2507</ArticleId><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-Bachiller M.I., Brzozowska I., Odolczyk N., Zielenkiewicz U., Zielenkiewicz P., Rademann J. Mapping Protein–Protein Interactions of the Resistance-Related Bacterial Zeta Toxin–Epsilon Antitoxin Complex (Ε2ζ2) with High Affinity Peptide Ligands Using Fluorescence Polarization. Toxins. 2016;8:222. doi: 10.3390/toxins8070222.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins8070222</ArticleId><ArticleId IdType="pmc">PMC4963854</ArticleId><ArticleId IdType="pubmed">27438853</ArticleId></ArticleIdList></Reference><Reference><Citation>Odolczyk N., Marzec E., Winiewska-Szajewska M., Poznański J., Zielenkiewicz P. Native Structure-Based Peptides as Potential Protein-Protein Interaction Inhibitors of SARS-CoV-2 Spike Protein and Human ACE2 Receptor. Molecules. 2021;26:2157. doi: 10.3390/molecules26082157.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26082157</ArticleId><ArticleId IdType="pmc">PMC8070189</ArticleId><ArticleId IdType="pubmed">33918595</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelay-Gimeno M., Glas A., Koch O., Grossmann T.N. Structure-Based Design of Inhibitors of Protein–Protein Interactions: Mimicking Peptide Binding Epitopes. Angew. Chem. Int. Ed. 2015;54:8896–8927. doi: 10.1002/anie.201412070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201412070</ArticleId><ArticleId IdType="pmc">PMC4557054</ArticleId><ArticleId IdType="pubmed">26119925</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei Araghi R., Keating A.E. Designing Helical Peptide Inhibitors of Protein–Protein Interactions. Curr. Opin. Struct. Biol. 2016;39:27–38. doi: 10.1016/j.sbi.2016.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2016.04.001</ArticleId><ArticleId IdType="pmc">PMC5282971</ArticleId><ArticleId IdType="pubmed">27123812</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho T.-Y., Wu S.-L., Chen J.-C., Wei Y.-C., Cheng S.-E., Chang Y.-H., Liu H.-J., Hsiang C.-Y. Design and Biological Activities of Novel Inhibitory Peptides for SARS-CoV Spike Protein and Angiotensin-Converting Enzyme 2 Interaction. Antivir. Res. 2006;69:70–76. doi: 10.1016/j.antiviral.2005.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2005.10.005</ArticleId><ArticleId IdType="pmc">PMC7114127</ArticleId><ArticleId IdType="pubmed">16337697</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y., Král P. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2. ACS Nano. 2020;14:5143–5147. doi: 10.1021/acsnano.0c02857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.0c02857</ArticleId><ArticleId IdType="pmc">PMC7163933</ArticleId><ArticleId IdType="pubmed">32286790</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling R., Dai Y., Huang B., Huang W., Yu J., Lu X., Jiang Y. In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2. Peptides. 2020;130:170328. doi: 10.1016/j.peptides.2020.170328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2020.170328</ArticleId><ArticleId IdType="pmc">PMC7198429</ArticleId><ArticleId IdType="pubmed">32380200</ArticleId></ArticleIdList></Reference><Reference><Citation>Larue R.C., Xing E., Kenney A.D., Zhang Y., Tuazon J.A., Li J., Yount J.S., Li P.-K., Sharma A. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2. Bioconjugate Chem. 2021;32:215–223. doi: 10.1021/acs.bioconjchem.0c00664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.bioconjchem.0c00664</ArticleId><ArticleId IdType="pmc">PMC7784661</ArticleId><ArticleId IdType="pubmed">33356169</ArticleId></ArticleIdList></Reference><Reference><Citation>Morse J.S., Lalonde T., Xu S., Liu W.R. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. ChemBioChem. 2020;21:730–738. doi: 10.1002/cbic.202000047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.202000047</ArticleId><ArticleId IdType="pmc">PMC7162020</ArticleId><ArticleId IdType="pubmed">32022370</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei P., Qin H., Chen J., Wang F., He C., He S., Hong B., Liu K., Qiao R., Fan H., et al. Computational Design of Ultrashort Peptide Inhibitors of the Receptor-Binding Domain of the SARS-CoV-2 S Protein. Brief. Bioinform. 2021;22:bbab243. doi: 10.1093/bib/bbab243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab243</ArticleId><ArticleId IdType="pubmed">34180984</ArticleId></ArticleIdList></Reference><Reference><Citation>Abouhajar F., Chaudhuri R., Valiulis S.N., Stuart D.D., Malinick A.S., Xue M., Cheng Q. Label-Free Analysis of Binding and Inhibition of SARS-CoV-19 Spike Proteins to ACE2 Receptor with ACE2-Derived Peptides by Surface Plasmon Resonance. ACS Appl. Bio Mater. 2022;6:182–190. doi: 10.1021/acsabm.2c00832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsabm.2c00832</ArticleId><ArticleId IdType="pmc">PMC9797021</ArticleId><ArticleId IdType="pubmed">36550079</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitsike L., Krstenansky J., Duerksen-Hughes P.J. ACE2 : S1 RBD Interaction-Targeted Peptides and Small Molecules as Potential COVID-19 Therapeutics. Adv. Pharmacol. Pharm. Sci. 2021;2021:1828792. doi: 10.1155/2021/1828792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/1828792</ArticleId><ArticleId IdType="pmc">PMC8564205</ArticleId><ArticleId IdType="pubmed">34746794</ArticleId></ArticleIdList></Reference><Reference><Citation>Karoyan P., Vieillard V., Gómez-Morales L., Odile E., Guihot A., Luyt C.-E., Denis A., Grondin P., Lequin O. Human ACE2 Peptide-Mimics Block SARS-CoV-2 Pulmonary Cells Infection. Commun. Biol. 2021;4:197. doi: 10.1038/s42003-021-01736-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-01736-8</ArticleId><ArticleId IdType="pmc">PMC7881012</ArticleId><ArticleId IdType="pubmed">33580154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolaskar A.S., Tongaonkar P.C. A Semi-Empirical Method for Prediction of Antigenic Determinants on Protein Antigens. FEBS Lett. 1990;276:172–174. doi: 10.1016/0014-5793(90)80535-Q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(90)80535-Q</ArticleId><ArticleId IdType="pubmed">1702393</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K.K., Dorosky D., Sharma P., Abbasi S.A., Dye J.M., Kranz D.M., Herbert A.S., Procko E. Engineering Human ACE2 to Optimize Binding to the Spike Protein of SARS Coronavirus 2. Science. 2020;369:1261–1265. doi: 10.1126/science.abc0870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc0870</ArticleId><ArticleId IdType="pmc">PMC7574912</ArticleId><ArticleId IdType="pubmed">32753553</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra A., Shukri A.H., Adhikary H., Lukinović V., Hoekstra M., Cowpland M., Biggar K.K. A Peptide Array Pipeline for the Development of Spike-ACE2 Interaction Inhibitors. Peptides. 2022;158:170898. doi: 10.1016/j.peptides.2022.170898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2022.170898</ArticleId><ArticleId IdType="pmc">PMC9585897</ArticleId><ArticleId IdType="pubmed">36279985</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpoot S., Ohishi T., Kumar A., Pan Q., Banerjee S., Zhang K.Y.J., Baig M.S. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. Drugs R D. 2021;21:273–283. doi: 10.1007/s40268-021-00357-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40268-021-00357-0</ArticleId><ArticleId IdType="pmc">PMC8319882</ArticleId><ArticleId IdType="pubmed">34324175</ArticleId></ArticleIdList></Reference><Reference><Citation>Odolczyk N., Klim J., Podsiadła-Białoskórska M., Winiewska-Szajewska M., Szolajska E., Zielenkiewicz U., Poznański J., Zielenkiewicz P. Improvement of Native Structure-Based Peptides as Efficient Inhibitors of Protein-Protein Interactions of SARS-CoV-2 Spike Protein and Human ACE2. Front. Mol. Biosci. 2022;9:983014. doi: 10.3389/fmolb.2022.983014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.983014</ArticleId><ArticleId IdType="pmc">PMC9555309</ArticleId><ArticleId IdType="pubmed">36250011</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez M.A. Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Antimicrob. Agents Chemother. 2020;64:10–1128. doi: 10.1128/AAC.01101-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01101-20</ArticleId><ArticleId IdType="pmc">PMC7449177</ArticleId><ArticleId IdType="pubmed">32631826</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinner C.D., Gottlieb R.L., Criner G.J., Arribas López J.R., Cattelan A.M., Soriano Viladomiu A., Ogbuagu O., Malhotra P., Mullane K.M., Castagna A., et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:1048–1057. doi: 10.1001/jama.2020.16349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16349</ArticleId><ArticleId IdType="pmc">PMC7442954</ArticleId><ArticleId IdType="pubmed">32821939</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig M.H., Ahmad K., Saeed M., Alharbi A.M., Barreto G.E., Ashraf G.M., Choi I. Peptide Based Therapeutics and Their Use for the Treatment of Neurodegenerative and Other Diseases. Biomed. Pharmacother. 2018;103:574–581. doi: 10.1016/j.biopha.2018.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.04.025</ArticleId><ArticleId IdType="pubmed">29677544</ArticleId></ArticleIdList></Reference><Reference><Citation>Heydari H., Golmohammadi R., Mirnejad R., Tebyanian H., Fasihi-Ramandi M., Moosazadeh Moghaddam M. Antiviral Peptides against Coronaviridae Family: A Review. Peptides. 2021;139:170526. doi: 10.1016/j.peptides.2021.170526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2021.170526</ArticleId><ArticleId IdType="pmc">PMC7931737</ArticleId><ArticleId IdType="pubmed">33676968</ArticleId></ArticleIdList></Reference><Reference><Citation>Nepali K., Sharma R., Sharma S., Thakur A., Liou J.-P. Beyond the Vaccines: A Glance at the Small Molecule and Peptide-Based Anti-COVID19 Arsenal. J. Biomed. Sci. 2022;29:65. doi: 10.1186/s12929-022-00847-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-022-00847-6</ArticleId><ArticleId IdType="pmc">PMC9444709</ArticleId><ArticleId IdType="pubmed">36064696</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahal A., Sonju J.J., Kousoulas K.G., Jois S.D. Peptides and Peptidomimetics as Therapeutic Agents for COVID-19. Pept. Sci. 2022;114:e24245. doi: 10.1002/pep2.24245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pep2.24245</ArticleId><ArticleId IdType="pmc">PMC8646791</ArticleId><ArticleId IdType="pubmed">34901700</ArticleId></ArticleIdList></Reference><Reference><Citation>Schütz D., Ruiz-Blanco Y.B., Münch J., Kirchhoff F., Sanchez-Garcia E., Müller J.A. Peptide and Peptide-Based Inhibitors of SARS-CoV-2 Entry. Adv. Drug Deliv. Rev. 2020;167:47–65. doi: 10.1016/j.addr.2020.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7665879</ArticleId><ArticleId IdType="pubmed">33189768</ArticleId></ArticleIdList></Reference><Reference><Citation>Panchal D., Kataria J., Patel K., Crowe K., Pai V., Azizogli A.-R., Kadian N., Sanyal S., Roy A., Dodd-o J., et al. Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV. Adv. Ther. 2021;4:2100104. doi: 10.1002/adtp.202100104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adtp.202100104</ArticleId><ArticleId IdType="pmc">PMC8420164</ArticleId><ArticleId IdType="pubmed">34514085</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah J.N., Guo G.-Q., Krishnan A., Ramesh M., Katari N.K., Shahbaaz M., Abdellattif M.H., Singh S.K., Dua K. Peptides-Based Therapeutics: Emerging Potential Therapeutic Agents for COVID-19. Therapies. 2022;77:319–328. doi: 10.1016/j.therap.2021.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.therap.2021.09.007</ArticleId><ArticleId IdType="pmc">PMC8498005</ArticleId><ArticleId IdType="pubmed">34689960</ArticleId></ArticleIdList></Reference><Reference><Citation>Maas M.N., Hintzen J.C.J., Löffler P.M.G., Mecinović J. Targeting SARS-CoV-2 Spike Protein by Stapled hACE2 Peptides. Chem. Commun. 2021;57:3283–3286. doi: 10.1039/D0CC08387A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0CC08387A</ArticleId><ArticleId IdType="pubmed">33651072</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Dawber R.S., Zhang P., Walko M., Wilson A.J., Wang X. Peptide-Based Inhibitors of Protein–Protein Interactions: Biophysical, Structural and Cellular Consequences of Introducing a Constraint. Chem. Sci. 2021;12:5977–5993. doi: 10.1039/D1SC00165E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1SC00165E</ArticleId><ArticleId IdType="pmc">PMC8098664</ArticleId><ArticleId IdType="pubmed">33995995</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucana M.C., Arruga Y., Petrachi E., Roig A., Lucchi R., Oller-Salvia B. Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics. Pharmaceutics. 2021;13:2065. doi: 10.3390/pharmaceutics13122065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13122065</ArticleId><ArticleId IdType="pmc">PMC8708026</ArticleId><ArticleId IdType="pubmed">34959346</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossino G., Marchese E., Galli G., Verde F., Finizio M., Serra M., Linciano P., Collina S. Peptides as Therapeutic Agents: Challenges and Opportunities in the Green Transition Era. Molecules. 2023;28:7165. doi: 10.3390/molecules28207165.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28207165</ArticleId><ArticleId IdType="pmc">PMC10609221</ArticleId><ArticleId IdType="pubmed">37894644</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.F., Poh C.L. Strategies to Improve the Physicochemical Properties of Peptide-Based Drugs. Pharm. Res. 2023;40:617–632. doi: 10.1007/s11095-023-03486-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-023-03486-0</ArticleId><ArticleId IdType="pubmed">36869247</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries R.D., Schmitz K.S., Bovier F.T., Predella C., Khao J., Noack D., Haagmans B.L., Herfst S., Stearns K.N., Drew-Bear J., et al. Intranasal Fusion Inhibitory Lipopeptide Prevents Direct-Contact SARS-CoV-2 Transmission in Ferrets. Science. 2021;371:1379–1382. doi: 10.1126/science.abf4896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4896</ArticleId><ArticleId IdType="pmc">PMC8011693</ArticleId><ArticleId IdType="pubmed">33597220</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira E.H., Monteleone-Cassiano A.C., Tavares L., Santos J.C., Lima T.M., Gomes G.F., Tanaka P.P., Monteiro C.J., Munuera M., Batah S.S., et al. A Mimetic Peptide of ACE2 Protects against SARS-CoV-2 Infection and Decreases Pulmonary Inflammation Related to COVID-19. Antivir. Res. 2024;229:105968. doi: 10.1016/j.antiviral.2024.105968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2024.105968</ArticleId><ArticleId IdType="pubmed">39004311</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan H., He S., Han P., Hong B., Liu K., Li M., Wang S., Tong Y. Cepharanthine: A Promising Old Drug against SARS-CoV-2. Adv. Biol. 2022;6:2200148. doi: 10.1002/adbi.202200148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adbi.202200148</ArticleId><ArticleId IdType="pmc">PMC9350037</ArticleId><ArticleId IdType="pubmed">35775953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata A., Shionyu-Mitsuyama C., Nakae S., Shionyu M., Ota M., Kanaya S., Hirokawa T., Nakajima S., Watashi K., Shirai T. Evaluating Cepharanthine Analogues as Natural Drugs against SARS-CoV-2. FEBS Open Bio. 2022;12:285–294. doi: 10.1002/2211-5463.13337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.13337</ArticleId><ArticleId IdType="pmc">PMC8727928</ArticleId><ArticleId IdType="pubmed">34850606</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B.A., Jones C.H., Welch V., True J.M. Outlook of Pandemic Preparedness in a Post-COVID-19 World. npj Vaccines. 2023;8:178. doi: 10.1038/s41541-023-00773-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00773-0</ArticleId><ArticleId IdType="pmc">PMC10662147</ArticleId><ArticleId IdType="pubmed">37985781</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>